CIK 1540358
Long positions in SEC Section 13(f) securities (US-listed stocks, ADRs and ETFs), largest first · Δ vs 2025-Q4. A lagged quarterly snapshot (filed ≤45 days after quarter-end); excludes shorts, options, cash, and shares listed only on non-US exchanges — foreign companies held via a US listing or ADR (e.g. Alibaba, TSMC) ARE included.
As filed = each book applied at its quarter-end (what the reported book did) · As copyable = applied at its statutory 45-day filing deadline (what a 13F follower could have earned).
Computing…
Hypothetical modeled performance constructed with hindsight — not actual results, and not indicative of future results. See the Disclaimer.
| Industry group | Weight | Names |
|---|---|---|
| Software | 59.92% | 3 |
| Pharmaceuticals & Biotechnology | 22.68% | 8 |
| Software & IT Services | 9.42% | 1 |
| Life Sciences Tools & Services | 5.31% | 1 |
| Health Care Providers & Services | 2.25% | 1 |
| Banks | 0.42% | 1 |
| Beverages | 0.00% | 1 |
| # | Ticker | Name | Sector | Weight |
|---|---|---|---|---|
| 1 | NAVN | Navan, Inc. | Information Technology | 28.95% |
| 2 | FIG | Figma, Inc. | Information Technology | 26.23% |
| 3 | META | Meta Platforms, Inc. | Communication Services | 9.42% |
| 4 | RVMD | Revolution Medicines, Inc. | Health Care | 6.94% |
| 5 | NAUT | Nautilus Biotechnology, Inc. | Health Care | 5.31% |
| 6 | XYZ | Block, Inc. | Information Technology | 4.74% |
| 7 | BIOA | BioAge Labs, Inc. | Health Care | 4.38% |
| 8 | MAZE | Maze Therapeutics, Inc. | Health Care | 3.94% |
| 9 | ERAS | Erasca, Inc. | Health Care | 3.59% |
| 10 | DMRA | Damora Therapeutics, Inc. | Health Care | 2.48% |
16/16 names classified · sector 100.0% of weight · industry 100.0% · mkt cap 70.1%; unclassified names shown, never dropped.
Sector is classified on each name's CURRENT fundamentals, not point-in-time — apparent sector drift can reflect the market re-rating a holding, not a manager trade. 13F is a lagged quarterly snapshot of long positions in US-listed securities only — foreign companies held via a US listing or ADR ARE included, but shares listed only on non-US exchanges (plus shorts, options and cash) are not. Latest quarter: 100.0% of the book is sector-classified (unclassified names shown, never dropped).
Only 14% of book weight classified — the grid is NOT representative of the whole book.
Classified: 14.2% of book weight (2/16 names) · unclassified 85.8%: NAVN, FIG, RVMD, NAUT, BIOA, MAZE, ERAS, DMRA, OMDA, CAMP +4 more. Size: cap 70/20/10 bands; style: value/growth composite on our own metrics — not Morningstar's model.
No contribution data for this period.
| # | Security | Shares | Value | Weight | Δ QoQ |
|---|---|---|---|---|---|
| 1 | NAVNNAVAN INC | 28,218,676 | $374M | 28.9% | ADD 4% |
| 2 | FIGFIGMA INC | 16,011,378 | $338M | 26.2% | HOLD |
| 3 | METAMETA PLATFORMS INC | 212,531 | $122M | 9.4% | HOLD |
| 4 | RVMDREVOLUTION MEDICINES INC | 921,099 | $90M | 6.9% | HOLD |
| 5 | NAUTNAUTILUS BIOTECHNOLOGY INC | 17,653,917 | $68M | 5.3% | HOLD |
| 6 | XYZBLOCK INC | 1,016,697 | $61M | 4.7% | HOLD |
| 7 | BIOABIOAGE LABS INC | 3,233,170 | $57M | 4.4% | HOLD |
| 8 | MAZEMAZE THERAPEUTICS INC | 1,702,225 | $51M | 3.9% | HOLD |
| 9 | ERASERASCA INC | 2,862,500 | $46M | 3.6% | HOLD |
| 10 | DMRADAMORA THERAPEUTICS INC | 1,236,157 | $32M | 2.5% | NEW |
| 11 | OMDAOMADA HEALTH INC | 2,307,284 | $29M | 2.2% | TRIM −33% |
| 12 | CAMPCAMP4 THERAPEUTICS CORP | 2,125,339 | $9M | 0.7% | HOLD |
| 13 | AKTSAKTIS ONCOLOGY INC | 415,000 | $7M | 0.6% | NEW |
| 14 | BTGOBITGO HOLDINGS INC | 666,356 | $5M | 0.4% | NEW |
| 15 | DNAGINKGO BIOWORKS HOLDINGS INC | 108,568 | $665,522 | 0.1% | HOLD |
| 16 | IPSTHERITAGE DISTILLING HLDG CO | 82,740 | $21,843 | 0.0% | NEW |
| Security | 2024-Q4 | 2025-Q1 | 2025-Q2 | 2025-Q3 | 2025-Q4 | 2026-Q1 | Latest value |
|---|---|---|---|---|---|---|---|
| NAVNNAVAN INC | — | — | — | — | 27.2M | 28.2M | $374M |
| FIGFIGMA INC | — | — | — | 16.2M | 16.2M | 16.0M | $338M |
| METAMETA PLATFORMS INC | — | — | — | 213K | 213K | 213K | $122M |
| RVMDREVOLUTION MEDICINES INC | 2.7M | 2.7M | 2.7M | 2.7M | 921K | 921K | $90M |
| NAUTNAUTILUS BIOTECHNOLOGY INC | 17.7M | 17.7M | 17.7M | 17.7M | 17.7M | 17.7M | $68M |
| XYZBLOCK INC | 1.0M | 1.0M | 1.0M | 1.0M | 1.0M | 1.0M | $61M |
| BIOABIOAGE LABS INC | 3.2M | 3.2M | 3.2M | 3.2M | 3.2M | 3.2M | $57M |
| MAZEMAZE THERAPEUTICS INC | — | 1.7M | 1.7M | 1.7M | 1.7M | 1.7M | $51M |
| ERASERASCA INC | 2.9M | 2.9M | 2.9M | 2.9M | 2.9M | 2.9M | $46M |
| DMRADAMORA THERAPEUTICS INC | — | — | — | — | — | 1.2M | $32M |
| OMDAOMADA HEALTH INC | — | — | 4.6M | 4.6M | 3.5M | 2.3M | $29M |
| CAMPCAMP4 THERAPEUTICS CORP | 2.1M | 2.1M | 2.1M | 2.1M | 2.1M | 2.1M | $9M |
| AKTSAKTIS ONCOLOGY INC | — | — | — | — | — | 415K | $7M |
| BTGOBITGO HOLDINGS INC | — | — | — | — | — | 666K | $5M |
| DNAGINKGO BIOWORKS HOLDINGS INC | 109K | 109K | 109K | 109K | 109K | 109K | $665,522 |
Shares reported each quarter by the largest current holdings. Green = added vs the prior filing of that name, red = trimmed, grey = roughly held; a dash is a quarter with no 13F on file (a gap is skipped, not read as an exit). 13F is filed up to 45 days after quarter-end. Up to 40 quarters (10 years) available — use the selector above.
Where this firm's principals came from and which firms its alumni went on to found.
